Corrigendum: Muscle-Specific CRISPR/Cas9 Dystrophin Gene Editing Ameliorates Pathophysiology in a Mouse Model for Duchenne Muscular Dystrophy

Nature Communications - United Kingdom
doi 10.1038/ncomms16007
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Genome Editing Gene Therapy for Duchenne Muscular Dystrophy

Journal of Neuromuscular Diseases
Neurology
2015English

Corrigendum: Reading Frame Correction by Targeted Genome Editing Restores Dystrophin Expression in Cells From Duchenne Muscular Dystrophy Patients

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2013English

Immune Responses to Dystrophin: Implications for Gene Therapy of Duchenne Muscular Dystrophy

Gene Therapy
Molecular MedicineGeneticsMolecular Biology
2000English

Improved Mouse Model for Studying Duchenne Muscular Dystrophy (DMD)

Science-Business eXchange
2010English

Muscle Dysfunction in a Zebrafish Model of Duchenne Muscular Dystrophy

Physiological Genomics
GeneticsPhysiology
2016English

Pathophysiology of Duchenne Muscular Dystrophy: Current Hypotheses

Pediatric Neurology
Child HealthDevelopmental NeurosciencePediatricsPerinatologyNeurology
2007English

Gene Therapy for Duchenne Muscular Dystrophy

Archives of Neurology
2007English

Prevention of Muscular Dystrophy in Mice by CRISPR/Cas9-mediated Editing of Germline DNA

Science
MultidisciplinaryPhilosophy of ScienceHistory
2014English

325. A Novel Utrophin-Based Genome Engineering Strategy for Duchenne Muscular Dystrophy Utilizing Recombinases and CRISPR/Cas9

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy